Wolfgang Merkt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3883800/publications.pdf

Version: 2024-02-01

		1478505	1372567	
11	165	6	10	
papers	citations	h-index	g-index	
12	12	12	196	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Senotherapeutics: Targeting senescence in idiopathic pulmonary fibrosis. Seminars in Cell and Developmental Biology, 2020, 101, 104-110.	5.0	64
2	Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting. Arthritis Research and Therapy, 2016, 18, 206.	3.5	20
3	Myofibroblast fate plasticity in tissue repair and fibrosis: Deactivation, apoptosis, senescence and reprogramming. Wound Repair and Regeneration, 2021, 29, 678-691.	3.0	20
4	Effect of <scp>JAK</scp> Inhibition on the Induction of Proinflammatory <scp>HLA</scp> â€" <scp>DR</scp> + <scp>CD90</scp> + Rheumatoid Arthritis Synovial Fibroblasts by Interferonâ€i³. Arthritis and Rheumatology, 2022, 74, 441-452.	5.6	20
5	Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Research and Therapy, 2015, 17, 337.	3.5	14
6	Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells. Arthritis Research and Therapy, 2016, 18, 204.	3.5	8
7	Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis Research and Therapy, 2019, 21, 277.	3.5	7
8	Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides. BMC Immunology, 2021, 22, 26.	2.2	6
9	Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Annals of the Rheumatic Diseases, 2022, 81, 744-746.	0.9	5
10	Leflunomide in combination with JAK-inhibitors in the treatment of rheumatoid arthritis: a case series. Rheumatology, 2022, , .	1.9	1
11	Rituximab and Fcl̂³ Receptors in Granulomatosis With Polyangiitis (Wegener's): Comment on the Article by Cartin eba et al. Arthritis and Rheumatology, 2017, 69, 1506-1507.	5.6	O